1. Home
  2. TBLA vs KALV Comparison

TBLA vs KALV Comparison

Compare TBLA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$4.99

Market Cap

952.2M

Sector

Technology

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.74

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBLA
KALV
Founded
2007
N/A
Country
United States
United States
Employees
2000
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
952.2M
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TBLA
KALV
Price
$4.99
$26.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$5.00
$32.60
AVG Volume (30 Days)
2.6M
4.5M
Earning Date
05-06-2026
07-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$7.63
$185.42
Revenue Next Year
$5.25
$59.23
P/E Ratio
$42.36
N/A
Revenue Growth
N/A
495.66
52 Week Low
$2.84
$9.83
52 Week High
$5.26
$26.85

Technical Indicators

Market Signals
Indicator
TBLA
KALV
Relative Strength Index (RSI) 75.23 74.83
Support Level $3.86 $14.56
Resistance Level N/A N/A
Average True Range (ATR) 0.23 0.15
MACD 0.08 0.01
Stochastic Oscillator 82.61 98.60

Price Performance

Historical Comparison
TBLA
KALV

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: